Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma

Xie, S. D.; Wang, Mengchao; Zeng, Chuanxiu; Ou, Yimeng; Zhao, Lu; Wang, Dong; Chen, Liwei; Kong, Fanming; Yi, Danhui

doi:10.3389/fonc.2023.1197698

Cited by 4 publications

(1 citation statement)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nowadays, with the application of tumor immunotherapy and immune checkpoint inhibitors, the treatment of tumors has made continuous progress. Immunotherapy can be used in the treatment of many kinds of malignant tumours to restore and improve the anti-tumour ability of the patient’s immune system, and it has fewer side effects compared with chemotherapy [ 8 , 9 ]. However, the biggest limitation of immunotherapy at present is its low efficiency, the efficiency of PD-1 is only 15–50% [ 10 , 11 ], drug resistance is difficult to overcome, currently it is only used for adjuvant therapy [ 12 ], so we have to actively search for new potential biomarkers, vaccines for immunotherapy and immune checkpoint inhibitors.…”

Section: Introductionmentioning

confidence: 99%

Cellular senescence-related genes: predicting prognosis in hepatocellular carcinoma

Yuan,

Xu,

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Recent studies have shown that the high incidence and low cure rate of hepatocellular carcinoma (HCC) have not improved significantly. Surgery and liver transplantation are the mainstays of prolonging the survival of HCC patients. However, the surgical resection rate of HCC patients is very low, and even after radical surgical resection, the recurrence rate at 5 years postoperatively remains high and the prognosis is very poor, so more treatment options are urgently needed. Increasing evidence suggests that cellular senescence is not only related to cancer development but may also be one of its primary driving factors. We aimed to establish a prognostic signature of senescence-associated genes to predict the prognosis and therapeutic response of HCC patients. The aim of this study was to develop a risk model associated with cellular senescence and to search for potential strategies to treat HCC. We divided HCC patients into two clusters and identified differentially expressed genes (DEGs) between clusters. In this study, low-risk patients had a better prognosis, higher levels of immune cell infiltration, and better efficacy to fluorouracil, Paclitaxel and Cytarabine chemotherapy compared to high-risk patients. To further identify potential biomarkers for HCC, we further validated the expression levels of the four signature genes in HCC and neighbouring normal tissues by in vitro experiments. In conclusion, we identified and constructed a relevant prognostic signature, which performed well in predicting the survival and treatment response of HCC patients. This helps to differentiate between low-score and high-risk HCC, and the results may contribute to precise treatment protocols in clinical practice.

show abstract